CAMBRIDGE, Mass. — March 5, 2026 — Leads & Copy — Wave Life Sciences Ltd. (Nasdaq: WVE) will present data from its RestorAATion-2 clinical trial of WVE-006, an investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the American Thoracic Society (ATS) International Conference in Orlando, Florida, May 15-20, 2026.
The presentation will include new data from the 400 mg multidose cohort and the 600 mg single dose cohort.
Wave Life Sciences expects to share data from the 600 mg single dose cohort, in addition to data from the 400 mg multidose cohort, at the ATS conference.
Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences, stated that the ATS conference is an important forum for fostering innovation in pulmonary care. He added that AATD is well suited for RNA editing because it is a single-gene disorder, and correcting the mutant RNA transcript in the liver directly addresses the root cause of both lung and liver manifestations of the disease.
Bolno also noted that Wave is advancing regulatory engagement on a potential accelerated approval pathway for WVE-006 and expects feedback mid-2026. Additionally, the company remains on track to deliver data from the INLIGHT trial of WVE-007 for obesity this month.
The oral presentation is titled “RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency.” The presenter is Kenneth R. Chapman, MsC, MD, FRCPC, FACP, FERS, Department of Medicine, University of Toronto. The presentation is scheduled for Monday, May 18, 2026, 4:03 – 4:15 p.m. ET.
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders.
The company’s toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with capabilities for designing and delivering candidates that address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s RNA medicines platform. Wave is headquartered in Cambridge, MA.
Source: Wave Life Sciences
